Severe combined immunodeficiency (SCID) conditions appear to be the best possible candidates for a gene therapy approach. Transgene expression by lymphocyte precursors should confer to these cells a selective growth advantage that gives rise to long-lived T-lymphocytes. This rationale was used as a basis for a clinical trial of the SCID-X1 disorder caused by common γ (γc) gene mutations. This trial consists of ex vivo retroviral-mediated (MFG-B2 γc vector) γc gene transfer into marrow CD34+ cells in CH-296 fibronectin fragment—coated bags. Up to now, 9 patients with typical SCID-X1 diagnosed within the first year of life and lacking an HLA-identical donor have been enrolled. More than 2 years’ assessment of 5 patients and more than 1 year for 7 patients provide evidence for full development of functional, mature T-cells in the absence of any adverse effects. Functional transduced natural killer cells are also detectable, although in low numbers. All but 1 patient with T-cell immunity have also developed immunoglobulin production, which has alleviated the need for intravenous immunoglobulin substitution despite a low detection frequency of transduced B-cells. These 8 patients are doing well and living in a normal environment. This yet successful gene therapy demonstrates that in a setting where transgene expression provides a selective advantage, a clinical benefit can be expected.Int J Hematol. 2002;76:295-298.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest.Hum Gene Ther. 2000;11:1259–1267.
Williams DA, Smith FO. Progress in the use of gene transfer methods to treat genetic blood diseases.Hum Gene Ther. 2000;11: 2059–2066.
Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I,Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.Nat Med. 1996;2:876–882.
Kelly PF,Vandergriff J, Nathwani A, Nienhuis AW,Vanin EF. Highly efficient gene transfer into cord blood nonobese diabetic/severe combined immunodeficiency repopulating cells by oncoretroviral vector particles pseudotyped with the feline endogenous retrovirus (RD114) envelope protein.Blood. 2000;96:1206–1214.
Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.Science. 1993;262:1877–1880.
Sugamura K, Asao H, Kondo M, et al. The common gamma-chain for multiple cytokine receptors.Adv Immunol. 1995;59:225–277.
Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function.Nature. 2000;408:57–63.
von Freeden-Jeffry U, Viera P, Lucian LA, McNeil T, Burdach SE, Murray R. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-7 as a nonredundant cytokine.J Exp Med. 1995;181: 1519–1526.
Di Santo JP, Kuhn R, Muller W. Common cytokine receptor gamma chain (gamma c)-dependent cytokines: understanding in vivo functions by gene targeting.Immunol Rev. 1995;148:19–34.
Fischer A. Thirty years of bone marrow transplantation for severe combined immunodeficiency.N Engl J Med. 1999;340:559–561.
Buckley RH, Schriff SE, Schriff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency.N Engl J Med. 1999;340:508–516.
Johnston JA, Bacon CM, Riedy MC, O’Shea JJ. Signaling by IL-2 and related cytokines: JAKs, STATs, and relationship to immunodeficiency.J Leukoc Biol. 1996;60:441–452.
Bousso P, Wahn V, Douagi I, et al. Diversity, functionality, and stability of the T cell repertoire derived in vivo from a single human T cell precursor.Proc Natl Acad Sci U S A. 2000;97:274–278.
Hacein-Bey S, Cavazzana-Calvo M, Le Deist F, et al. gamma-c gene transfer into SCID X1 patients’ B-cell lines restores normal highaffinity interleukin-2 receptor expression and function.Blood. 1996;87:3108–3116.
Hacein-Bey S, Basile GD, Lemerle J, Fischer A, Cavazzana-Calvo M. Gammac gene transfer in the presence of stem cell factor, FLT-3L, interleukin-7 (IL-7), IL-1, and IL-15 cytokines restores T-cell differentiation from gammac(-) X-linked severe combined immunodeficiency hematopoietic progenitor cells in murine fetal thymic organ cultures.Blood. 1998;92:4090–4097.
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells.Blood. 1996;88:3901–3909.
Soudais C, Shiho T, Sharara LI, et al. Stable and functional lymphoid reconstitution of common cytokine receptor gamma chain deficient mice by retroviral-mediated gene transfer.Blood. 2000; 95:3071–3077.
Lo M, Bloom ML, Imada K, et al. Restoration of lymphoid populations in a murine model of X-linked severe combined immunodeficiency by a gene-therapy approach.Blood. 1999;94:3027–3036.
Bunting KD, Sangster MY, Ihle JN, Sorrentino BP. Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviralmediated gene transfer.Nat Med. 1998;4:58–64.
Bunting KD, Lu T, Kelly PF, Sorrentino BP. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation.Hum Gene Ther. 2000;11:2353–2364.
Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1disease. Science. 2000;288:669–672.
Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.N Engl J Med. 2002;346:1185–1193.
Otsu M, Sugamura K, Candotti F. Lack of dominant-negative effects of a truncated gamma(c) on retroviral-mediated gene correction of immunodeficient mice.Blood. 2001;97:1618–1624.
Kong F, Chen CH, Cooper MD. Thymic function can be accurately monitored by the level of recent T cell emigrants in the circulation.Immunity. 1998;8:97–104.
Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection.Nature. 1998;396:690–695.
Haddad E, Le Deist F, Aucouturier P, et al. Long-term chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single-cen- ter study of 22 patients.Blood. 1999;94:2923–2930.
Izuhara K, Heike T, Otsuka T, et al. Signal transduction pathway of interleukin-4 and interleukin-13 in human B cells derived from X- linked severe combined immunodeficiency patients.J Biol Chem. 1996;271:619–622.
White H, Thrasher A, Veys P, Kinnon C, Gaspar HB. Intrinsic defects of B cell function in X-linked severe combined immunodeficiency.Eur J Immunol. 2000;30:732–737.
Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients.Blood. 1998; 91:3646–3653.
About this article
Cite this article
Hacein-Bey-Abina, S., Fischer, A. & Cavazzana-Calvoa, M. Gene Therapy of X-Linked Severe Combined Immunodeficiency. Int J Hematol 76, 295–298 (2002). https://doi.org/10.1007/BF02982686
- Gene transfer
- γc Chain
- Selective advantage
- Retroviral vector